| Reaction Details |
|---|
 | Report a problem with these data |
| Target | Mu-type opioid receptor |
|---|
| Ligand | BDBM50261729 |
|---|
| Substrate/Competitor | n/a |
|---|
| Meas. Tech. | ChEMBL_514297 (CHEMBL979127) |
|---|
| EC50 | >50000±n/a nM |
|---|
| Citation |  DiMauro, EF; Buchanan, JL; Cheng, A; Emkey, R; Hitchcock, SA; Huang, L; Huang, MY; Janosky, B; Lee, JH; Li, X; Martin, MW; Tomlinson, SA; White, RD; Zheng, XM; Patel, VF; Fremeau, RT Structural modifications of N-arylamide oxadiazoles: Identification of N-arylpiperidine oxadiazoles as potent and selective agonists of CB2. Bioorg Med Chem Lett18:4267-74 (2008) [PubMed] Article |
|---|
| More Info.: | Get all data from this article, Assay Method |
|---|
| |
| Mu-type opioid receptor |
|---|
| Name: | Mu-type opioid receptor |
|---|
| Synonyms: | M-OR-1 | MOP | MOR-1 | MOR1 | MUOR1 | Mu Opioid Receptor | Mu opiate receptor | OPIATE Mu | OPRM1 | OPRM_HUMAN | hMOP | mu-type opioid receptor isoform MOR-1 |
|---|
| Type: | G Protein-Coupled Receptor (GPCR) |
|---|
| Mol. Mass.: | 44789.51 |
|---|
| Organism: | Homo sapiens (Human) |
|---|
| Description: | P35372 |
|---|
| Residue: | 400 |
|---|
| Sequence: | MDSSAAPTNASNCTDALAYSSCSPAPSPGSWVNLSHLDGNLSDPCGPNRTDLGGRDSLCP
PTGSPSMITAITIMALYSIVCVVGLFGNFLVMYVIVRYTKMKTATNIYIFNLALADALAT
STLPFQSVNYLMGTWPFGTILCKIVISIDYYNMFTSIFTLCTMSVDRYIAVCHPVKALDF
RTPRNAKIINVCNWILSSAIGLPVMFMATTKYRQGSIDCTLTFSHPTWYWENLLKICVFI
FAFIMPVLIITVCYGLMILRLKSVRMLSGSKEKDRNLRRITRMVLVVVAVFIVCWTPIHI
YVIIKALVTIPETTFQTVSWHFCIALGYTNSCLNPVLYAFLDENFKRCFREFCIPTSSNI
EQQNSTRIRQNTRDHPSTANTVDRTNHQLENLEAETAPLP
|
|
|
|---|
| BDBM50261729 |
|---|
| n/a |
|---|
| Name | BDBM50261729 |
|---|
| Synonyms: | 6-chloro-3-(4-(3-(2-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)quinoline | CHEMBL468176 |
|---|
| Type | Small organic molecule |
|---|
| Emp. Form. | C22H17Cl2FN4O |
|---|
| Mol. Mass. | 443.301 |
|---|
| SMILES | Fc1ccc(-c2noc(n2)C2CCN(CC2)c2cnc3ccc(Cl)cc3c2)c(Cl)c1 |
|---|
| Structure | 
|
|---|
Search and Browse
